| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 5.98 | 1.05 | 19.72 | 26.96 |
Op profit growth | -1.36 | 21.68 | -2.25 | 49.52 |
EBIT growth | 3.23 | 25.54 | -9.12 | 45.94 |
Net profit growth | 110.31 | 81.33 | -33.74 | 19.36 |
Profitability ratios (%) | ||||
OPM | 21.88 | 23.51 | 19.52 | 23.91 |
EBIT margin | 18.68 | 19.18 | 15.44 | 20.34 |
Net profit margin | 29.39 | 14.81 | 8.25 | 14.91 |
RoCE | 12.65 | 13.22 | 12.07 | 16.17 |
RoNW | 7.48 | 4.56 | 3.07 | 5.65 |
RoA | 4.97 | 2.55 | 1.61 | 2.96 |
Per share ratios (₹) | ||||
EPS | 44.65 | 20.87 | 11.48 | 17.07 |
Dividend per share | 2.5 | 3.5 | 3.5 | 3.5 |
Cash EPS | 36.86 | 14.3 | 4.68 | 12.08 |
Book value per share | 166.05 | 126.9 | 101.35 | 85.41 |
Valuation ratios | ||||
P/E | 7.8 | 21.12 | 23.26 | 22.18 |
P/CEPS | 9.45 | 30.82 | 56.95 | 31.33 |
P/B | 2.09 | 3.47 | 2.63 | 4.43 |
EV/EBIDTA | 10.88 | 14.23 | 11.86 | 14.47 |
Payout (%) | ||||
Dividend payout | 0 | 0 | 0 | 20.17 |
Tax payout | -18.77 | -7.43 | -17.2 | -24.21 |
Liquidity ratios | ||||
Debtor days | 77.32 | 86.03 | 87.95 | 84.06 |
Inventory days | 83.15 | 76.34 | 66.25 | 64.21 |
Creditor days | -69.99 | -74.42 | -65.7 | -73.35 |
Leverage ratios | ||||
Interest coverage | -22.45 | -17.39 | -6.43 | -26.58 |
Net debt / equity | 0.18 | 0.28 | 0.67 | 0.46 |
Net debt / op. profit | 0.93 | 1.09 | 2.52 | 1.43 |
Cost breakup (₹) | ||||
Material costs | -36.32 | -33.33 | -34.51 | -34.62 |
Employee costs | -15.94 | -15.93 | -16.94 | -15.57 |
Other costs | -25.84 | -27.21 | -29.01 | -25.87 |
In its filing with the bourses, Zydus informed that these observations received were minor, and not related to data integrity.
Here are some of the stocks that may see significant price movement today: Jio Financial Service, Hero MotoCorp, Abbott India, etc.
Here are some of the stocks that may see significant price movement today: Hindustan Copper, Maruti Suzuki, Zydus Lifesciences, etc.
For Zydus, this clean report adds a layer of credibility to its US compliance track record especially since the Ankleshwar facility is a key site for its API exports.
The acquisition is priced at $7.50 per share and will be completed in cash within 60 days, subject to regulatory approvals
It provides benefits such as faster approval, priority review and a more open line of communication with the F.D.A.
They are the generic form of Absorica, a well-known prescription treatment for severe and hard to treat forms of nodular acne that the patient has not responded well to other treatments with.
Consolidated revenue for the March quarter rose 18% YoY to ₹6,528 crore.
The medication is also prescribed to lower the risk of another heart attack in individuals with a past history of myocardial infarction and hyperlipidaemia
USFDA's final approval is available for Zydus Lifesciences and group companies, and this will allow the group to sell the product in the highly regulated US market.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
